AIM ImmunoTech Inc
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for … Read more
AIM ImmunoTech Inc (AIM) - Net Assets
Latest net assets as of March 2025: $-3.86 Million USD
Based on the latest financial reports, AIM ImmunoTech Inc (AIM) has net assets worth $-3.86 Million USD as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.25 Million) and total liabilities ($10.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.86 Million |
| % of Total Assets | -61.73% |
| Annual Growth Rate | N/A |
| 5-Year Change | -102.16% |
| 10-Year Change | -106.49% |
| Growth Volatility | 117.76 |
AIM ImmunoTech Inc - Net Assets Trend (1995–2024)
This chart illustrates how AIM ImmunoTech Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AIM ImmunoTech Inc (1995–2024)
The table below shows the annual net assets of AIM ImmunoTech Inc from 1995 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-1.32 Million | -112.92% |
| 2023-12-31 | $10.23 Million | -73.40% |
| 2022-12-31 | $38.47 Million | -32.37% |
| 2021-12-31 | $56.88 Million | -7.20% |
| 2020-12-31 | $61.29 Million | +374.89% |
| 2019-12-31 | $12.91 Million | +149.46% |
| 2018-12-31 | $5.17 Million | -40.55% |
| 2017-12-31 | $8.70 Million | -43.84% |
| 2016-12-31 | $15.50 Million | -23.92% |
| 2015-12-31 | $20.37 Million | -18.53% |
| 2014-12-31 | $25.00 Million | -14.66% |
| 2013-12-31 | $29.30 Million | -34.46% |
| 2012-12-31 | $44.70 Million | +17.74% |
| 2011-12-31 | $37.97 Million | -17.37% |
| 2010-12-31 | $45.95 Million | -26.34% |
| 2009-12-31 | $62.38 Million | +440.36% |
| 2008-12-31 | $11.54 Million | -44.91% |
| 2007-12-31 | $20.95 Million | -15.34% |
| 2006-12-31 | $24.75 Million | +24.77% |
| 2005-12-31 | $19.84 Million | -1.22% |
| 2004-12-31 | $20.08 Million | +117.14% |
| 2003-12-31 | $9.25 Million | +102.10% |
| 2002-12-31 | $4.58 Million | -57.48% |
| 2001-12-31 | $10.76 Million | -6.99% |
| 2000-12-31 | $11.57 Million | -8.88% |
| 1999-12-31 | $12.70 Million | -16.45% |
| 1998-12-31 | $15.20 Million | +42.06% |
| 1997-12-31 | $10.70 Million | +81.36% |
| 1996-12-31 | $5.90 Million | +34.09% |
| 1995-12-31 | $4.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to AIM ImmunoTech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 38332800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $425.51 Million | % |
| Total Equity | $-1.32 Million | 100.00% |
AIM ImmunoTech Inc Competitors by Market Cap
The table below lists competitors of AIM ImmunoTech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Natural Capsules Limited
NSE:NATCAPSUQ
|
$6.23 Million |
|
Jeju Beer Co. Ltd.
KQ:276730
|
$6.23 Million |
|
2BO
F:2BO
|
$6.23 Million |
|
Kanoria Chemicals & Industries Limited
NSE:KANORICHEM
|
$6.24 Million |
|
Zhong Yang Financial Group Limited Ordinary Shares
NASDAQ:TOP
|
$6.23 Million |
|
CATERPILLAR - Dusseldorf Stock Exchang
DU:CAT1
|
$6.23 Million |
|
Malam Team
TA:MLTM
|
$6.23 Million |
|
Aureka Ltd
AU:AKA
|
$6.23 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AIM ImmunoTech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 10,234,000 to -1,322,000, a change of -11,556,000 (-112.9%).
- Net loss of 17,320,000 reduced equity.
- New share issuances of 892,000 increased equity.
- Other factors increased equity by 4,872,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-17.32 Million | -1310.14% |
| Share Issuances | $892.00K | +67.47% |
| Other Changes | $4.87 Million | +368.53% |
| Total Change | $- | -112.92% |
Book Value vs Market Value Analysis
This analysis compares AIM ImmunoTech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | $139.39 | $0.09 | x |
| 1996-12-31 | $198.20 | $0.09 | x |
| 1997-12-31 | $324.16 | $0.09 | x |
| 1998-12-31 | $351.81 | $0.09 | x |
| 1999-12-31 | $254.20 | $0.09 | x |
| 2000-12-31 | $208.88 | $0.09 | x |
| 2001-12-31 | $180.80 | $0.09 | x |
| 2002-12-31 | $59.74 | $0.09 | x |
| 2003-12-31 | $138.59 | $0.09 | x |
| 2004-12-31 | $234.70 | $0.09 | x |
| 2005-12-31 | $203.48 | $0.09 | x |
| 2006-12-31 | $211.42 | $0.09 | x |
| 2007-12-31 | $154.02 | $0.09 | x |
| 2008-12-31 | $81.12 | $0.09 | x |
| 2009-12-31 | $300.75 | $0.09 | x |
| 2010-12-31 | $181.02 | $0.09 | x |
| 2011-12-31 | $148.01 | $0.09 | x |
| 2012-12-31 | $167.37 | $0.09 | x |
| 2013-12-31 | $92.45 | $0.09 | x |
| 2014-12-31 | $70.12 | $0.09 | x |
| 2015-12-31 | $45.55 | $0.09 | x |
| 2016-12-31 | $31.25 | $0.09 | x |
| 2017-12-31 | $13.35 | $0.09 | x |
| 2018-12-31 | $5.15 | $0.09 | x |
| 2019-12-31 | $3.54 | $0.09 | x |
| 2020-12-31 | $1.92 | $0.09 | x |
| 2021-12-31 | $1.20 | $0.09 | x |
| 2022-12-31 | $0.80 | $0.09 | x |
| 2023-12-31 | $0.21 | $0.09 | x |
| 2024-12-31 | $-0.02 | $0.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AIM ImmunoTech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -10188.24%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-80.27%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | -40.91% | -60.00% | 0.24x | 2.89x | $-2.24 Million |
| 1996 | -77.97% | -4600.00% | 0.01x | 1.19x | $-5.19 Million |
| 1997 | -57.01% | -2033.33% | 0.03x | 1.07x | $-7.17 Million |
| 1998 | -48.03% | -1825.00% | 0.02x | 1.07x | $-8.82 Million |
| 1999 | -72.44% | -1314.29% | 0.05x | 1.12x | $-10.47 Million |
| 2000 | -73.90% | -1085.28% | 0.06x | 1.13x | $-9.71 Million |
| 2001 | -84.39% | -2328.97% | 0.03x | 1.12x | $-10.16 Million |
| 2002 | -204.52% | -2177.13% | 0.06x | 1.66x | $-7.79 Million |
| 2003 | -159.71% | -2248.10% | 0.05x | 1.45x | $-15.69 Million |
| 2004 | -120.21% | -1964.20% | 0.05x | 1.25x | $-26.15 Million |
| 2005 | -66.61% | -1220.04% | 0.04x | 1.24x | $-15.20 Million |
| 2006 | -78.38% | -2079.21% | 0.03x | 1.27x | $-21.87 Million |
| 2007 | -86.56% | -1712.84% | 0.05x | 1.10x | $-20.23 Million |
| 2008 | -105.85% | -4610.94% | 0.02x | 1.14x | $-13.37 Million |
| 2009 | -21.54% | -12106.31% | 0.00x | 1.04x | $-19.68 Million |
| 2010 | -28.59% | -9730.37% | 0.00x | 1.12x | $-17.73 Million |
| 2011 | -23.75% | -5599.38% | 0.00x | 1.15x | $-12.81 Million |
| 2012 | -38.82% | -8147.42% | 0.00x | 1.29x | $-21.82 Million |
| 2013 | -55.38% | -10816.67% | 0.00x | 1.09x | $-19.15 Million |
| 2014 | -69.79% | -8857.87% | 0.01x | 1.18x | $-19.95 Million |
| 2015 | -74.76% | -11451.13% | 0.01x | 1.12x | $-17.27 Million |
| 2016 | -48.41% | -8154.35% | 0.00x | 1.22x | $-9.05 Million |
| 2017 | -94.90% | -1889.93% | 0.03x | 1.63x | $-9.13 Million |
| 2018 | -189.66% | -2673.84% | 0.03x | 2.68x | $-10.33 Million |
| 2019 | -83.88% | -7732.86% | 0.01x | 1.57x | $-12.12 Million |
| 2020 | -26.52% | -9974.23% | 0.00x | 1.05x | $-22.39 Million |
| 2021 | -37.82% | -15935.56% | 0.00x | 1.01x | $-27.20 Million |
| 2022 | -54.81% | -14954.61% | 0.00x | 1.05x | $-24.93 Million |
| 2023 | -283.00% | -14337.62% | 0.01x | 1.89x | $-29.99 Million |
| 2024 | 0.00% | -10188.24% | 0.02x | 0.00x | $-17.19 Million |
Industry Comparison
This section compares AIM ImmunoTech Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AIM ImmunoTech Inc (AIM) | $-3.86 Million | -40.91% | N/A | $6.23 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |